The firm recently kicked off a study to determine whether a set of RNA-expression biomarkers can provide a high negative predictive value to rule out sepsis.
The firm completed a clinical study to apply for US regulatory clearance for FebriDx, its single-use, instrument-free assay for respiratory infections.
Arquer's assays use mouse monoclonal antibodies to detect levels of MCM5 proteins in cells exfoliated into urine to detect either bladder or endometrial cancers.
The firm has obtained CE marking for its automated, sample-to-answer Vidas TB-IGRA test for latent TB and is preparing a submission for FDA clearance.
The firm said a test it has developed on the back of a large clinical trial detected cardioembolic stroke with 90 percent sensitivity and 70 percent specificity.
The firm had to delay an FDA EUA submission for a COVID-19 assay and extended the timeline for the anticipated launch of its COVID-19-flu molecular diagnostic test.
The firm said it sees an increasing focus among hospital antimicrobial stewardship teams on how to manage sepsis and other infectious diseases beyond COVID-19.
The firm expects that next year it will launch the final version of a battery-powered instrument that can perform high-level multiplexing and provide test results in 30 minutes.
During its annual strategic planning, the firm identified its expanding base of MDx instruments as an essential driver of increasing revenues.
Acquired by private equity investor Martis Capital last year, DCN completed two strategic acquisitions last month, and it is pursuing others.